Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 45258J102 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
| Roivant Sciences Ltd. 13D/A | 55.9% |
12/12/2025
Event 12/12/2025
|
||
|
FMR LLC
13G/A
|
8.4% |
11/5/2025
Event 9/30/2025
|
||
| FMR LLC | 8.4% | |||
| Abigail P. Johnson | 8.4% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
|
Deep Track Capital, LP
13G/A
|
4.6% |
8/14/2026
Event 6/30/2026
|
||
| Deep Track Capital, LP | 4.6% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 4.6% | |||
| David Kroin | 4.6% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 5 | 4.62 M | $156 M |
| 2026 Q2 | 242 | 114 M | $4.34 B |
| 2026 Q1 | 232 | 111 M | $2.77 B |
| 2025 Q4 | 215 | 109 M | $2.78 B |
| 2025 Q3 | 203 | 95.3 M | $1.54 B |
| 2025 Q2 | 184 | 96.3 M | $1.54 B |
| 2025 Q1 | 219 | 94.8 M | $1.62 B |
| 2024 Q4 | 213 | 82.3 M | $2.04 B |
| 2024 Q3 | 211 | 79.7 M | $2.27 B |
| 2024 Q2 | 223 | 76.5 M | $2.02 B |
| 2024 Q1 | 245 | 75.0 M | $2.42 B |
| 2023 Q4 | 264 | 72.0 M | $3.03 B |
| 2023 Q3 | 223 | 69.4 M | $2.67 B |
| 2023 Q2 | 162 | 56.9 M | $1.08 B |
| 2023 Q1 | 155 | 58.3 M | $905 M |
| 2022 Q4 | 143 | 59.7 M | $1.06 B |
| 2022 Q3 | 118 | 42.7 M | $238 M |
| 2022 Q2 | 100 | 40.1 M | $157 M |
| 2022 Q1 | 122 | 43.4 M | $240 M |
| 2021 Q4 | 131 | 38.0 M | $324 M |
| 2021 Q3 | 134 | 33.8 M | $294 M |
| 2021 Q2 | 134 | 38.6 M | $408 M |
| 2021 Q1 | 134 | 40.4 M | $654 M |
| 2020 Q4 | 151 | 40.6 M | $1.88 B |
| 2020 Q3 | 119 | 39.8 M | $1.40 B |
| 2020 Q2 | 90 | 28.6 M | $696 M |
| 2020 Q1 | 42 | 12.6 M | $194 M |
| 2019 Q4 | 26 | 11.6 M | $176 M |